Franco J. Vizeacoumar

This study identifies four host-directed drugs and the NRAS/Raf/MEK/ERK pathway as critical for SARS-CoV-2 replication through CRISPR knockout screens in human lung cells.

This paper uses patient-derived pancreatic cancer organoids to identify drug sensitivities linked to tumor differentiation and pathway mutations, revealing new therapeutic targets in chemoresistant tumors.

The paper identifies synthetic dosage lethality targets for PLK1-overexpressing cancers using genome-wide screens and validates key hits to show their therapeutic potential.

This study identifies Neurog2 as a potential therapeutic target for MYCN-driven neuroendocrine prostate cancer by showing its role in promoting tumor growth and NEPC development.

This paper develops a SARS-CoV-2 reverse genetics system and lung cell lines for studying virus replication, antiviral screening, and host interactions.